Overview

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Status:
Recruiting
Trial end date:
2026-02-27
Target enrollment:
Participant gender:
Summary
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Lenalidomide
Pomalidomide
Thalidomide